Product Name: Human CCR4 Antibody (Mogamulizumab, Research Use)
Catalog Number: NBR-0120
Target Name: CCR4
Trade Name: Mogamulizumab
Antibody Drug Description: Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4). The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: CCR4
Synonyms: CC-CKR-4; CMKBR4; K5-5; ChemR13; CD194; CKR4
Target Description: CCR4 (C-C Motif Chemokine Receptor 4) is a Protein Coding gene. Diseases associated with CCR4 include Mycosis Fungoides and Peripheral T-Cell Lymphoma. Among its related pathways are Class A/1 (Rhodopsin-like receptors) and GPCR downstream signalling. Gene Ontology (GO) annotations related to this gene include G protein-coupled receptor activity and C-C chemokine receptor activity. An important paralog of this gene is CCR1.
Ensembl: ENSG00000183813
Uniprot: P51679